LB Pharmaceutical, a neuropsychiatric-focused biotech, saw its stock close at $17.30 on its first day of trading, a 15.33% gain.
Why it matters: Investors were rewarded in LB's successful debut, which was largely seen as a bellwether for the industry after six-plus months without an IPO.
